Criteria Bio Ventures

Pleased to have participated in the oversubscribed $17.2M seed financing of Tolerance Bio, a Philadelphia based #biopharma pioneering thymus-based therapies for immune-mediated diseases. News here: tolerancebio.com/recent-news/to… #portfolionews #venturecapital #biotech #immunology

@sanofi @Amgen Proud to welcome Tolerance Bio to our portfolio and support its innovative programs in the exciting field of thymus-based therapies! Learn more about Tolerance Bio & this financing: tolerancebio.com/recent-news/to… #portfolionews #venturecapital #lifesciences #financing #autoimmunity

@sanofi @Amgen Tolerance Bio is developing an allogeneic, or “off the shelf”, thymus iPSC-based #celltherapy platform along w pharmacological thymus therapies to address immune-mediated diseases caused by abnormalities in immune tolerance like autoimmune diseases, transplant rejection & cancer

Pleased to have participated in the oversubscribed $17.2M seed financing of Tolerance Bio, a Philadelphia based #biopharma pioneering thymus-based therapies for immune-mediated diseases. News here: tolerancebio.com/recent-news/to… #portfolionews #venturecapital #biotech #immunology

Proud sponsors one more edition of @CataloniaBioHT #BBQ2024. See you all next week at one of the best #biotech summer events in town!

📢Pablo Cironi (@CriteriaBioVC) resume los highlights de su intervención y el papel de Caixa Capital Risk 📍Taller 'Introducción a la Innovación y Transferencia en Biomedicina y Salud' de ASEICA-@FundlaCaixa @msmelanoma  ℹ️:aseica.es/diez-investiga…

We are attending @AseBio Investor Day! A fantastic event to feel the pulse of the Spanish biotech ecosystem. #AseBioID2024

Next week we will be attending #BioEquityEurope 2024 in San Sebastian to meet #biotech entrepreneurs and catch up with #pharma industry leaders and fellow #venturecapital investors. If you are also participating, get in touch with us to arrange a meet up! 🤝

Today we attended the second edition of @CataloniaBioHT #ConnectionDay24

Next week we will be attending #BIOEuropeSpring 2024 in Barcelona to meet #biotech entrepreneurs and catch up with #pharma industry leaders and fellow #venturecapital investors. If you are also participating, get in touch with us to arrange a meet up! 🤝

Thrilled to announce the well-deserved promotions of @RubenSebas_ and Salvatore Cappadona to Senior Associates within our investment team 🚀 Their exceptional talent and invaluable contributions have been instrumental in driving our mission forward. Congrats Ruben & Salvatore!

Today Pablo Cironi, Managing Director, and @RubenSebas_, Sr Associate, are representing @CriteriaBioVC at CNIO Investor's Day 2024. A great event to interact with the scientists of one of the leading cancer research centers worldwide. @CNIOStopCancer #cancertherapy #innovation

Our portfolio company @Inbiomotion and @SourceBio have signed an exclusive agreement for MAF Test® in the UK and Ireland. The MAF Test® will benefit ~56,000 new #breastcancer patients each year. More info 👉 inbiomotion.com/documents/2402… #CBVnews #portfolionews #oncology

#tbt last year we welcomed AbolerIS Pharma! We led the €27.3M Series A round of AbolerIS, a Belgian #biotech developing a novel immunotherapy for autoimmune and inflammatory diseases. #CBVnews #portfolionews #immunology #autoimmunity #venturecapital aboleris-pharma.com/aboleris-pharm…

Meet the @CriteriaBioVC team! Stay informed about the latest news from our portfolio. Follow us on this new account for updates on our #biotech and #lifesciences investments and team activities! @CriteriaBioVC web➡️ goo.su/N3bW2 #biotech #lifesciences #pharma

We are launching new @X profiles! From today we will share our #VC activity on #Tech topics from the account @CriteriaVT. Everything related to #Biotech and #LifeSciences will be available at @CriteriaBioVC. Follow us ⬇️! 🔬goo.su/N3bW2 🤖goo.su/m60dOF

Exciting news! Our new website is live, providing a fresh look into Criteria Bio Ventures. Follow us for updates on our portfolio, team activities, and more. Let the journey begin! 🚀 #CBVnews #venturecapital #biotech #lifesciences #pharma criteriabioventures.com